Table 1 Patient characteristics of the abn(7) cohort
Baseline patient characteristics | All patients, n = 519 | Intensively treated patients, n = 415 |
|---|---|---|
Sex | ||
 Female | 233 (45%) | 189 (46%) |
 Male | 286 (55%) | 226 (54%) |
Age (years) | ||
 Median (IQR) | 59 (47, 69) | 55 (44, 64) |
AML type | ||
 De novo | 404 (78%) | 336 (81%) |
 Secondary | 75 (14%) | 47 (11%) |
 Therapy-related | 39 (7%) | 31 (7%) |
 Missing data | 1 (< 1%) | 1 (< 1%) |
ELN risk category [3] | ||
 Favorable | 11 (2%) | 11 (3%) |
 Intermediate | 31 (6%) | 24 (6%) |
 Adverse | 475 (92%) | 378 (91%) |
 Missing data | 2 (< 1%) | 2 (< 1%) |
WBC at diagnosis (/nL) | ||
 Median (IQR) | 9 (3, 30) | 9 (3, 30) |
 Missing data | 14 (3%) | 9 (2%) |
Blast count at diagnosis (%) | ||
 Median (IQR) | 55 (33, 80) | 58 (37, 82) |
 Missing data | 46 (9%) | 31 (7%) |
Platelets at diagnosis (/nL) | ||
 Median (IQR) | 47 (24, 96) | 52 (24, 102) |
 Missing data | 49 (9%) | 43 (10%) |
Hemoglobin at diagnosis (g/dL) | ||
 Median (IQR) | 8.5 (7.15, 9.7) | 8.5 (7.1, 9.9) |
 Missing data | 108 (21%) | 102 (24%) |
Intensive treatment | Â | Â |
 Yes | 415 (80%) | 415 (100%) |
 No | 100 (19%) | – |
 Missing data | 4 (1%) | – |
Complete remission | ||
 Yes | 268 (52%) | 253 (61%) |
 No | 249 (48%) | 160 (39%) |
 Missing data | 2 (< 1%) | 2 (< 1%) |
Allo-HSCT | ||
 In CR1 | 126 (24%) | 123 (30%) |
 Non-CR1/Salvage | 38 (7%) | 34 (8%) |
 Unknown timepoint | 6 (1%) | 6 (1%) |
 No | 301 (58%) | 208 (50%) |
 Missing data | 48 (9%) | 44 (11%) |
Treatment within trial | ||
 Yes | 276 (53%) | 275 (66%) |
 No | 239 (46%) | 139 (34%) |
 Missing data | 4 (1%) | 1 (< 1%) |